US GDP report to show if economy expanded in last quarter, after eurozone growth accelerates – business live


All eyes on US GDP coming up soon….

Tension is building in the markets are investors await the first estimate of how the US economy fared in January to March this year.

The official estimate of US GDP for Q1 2025 is due in just under 30 minutes (8.30am on the East coast of the US, or 1.30pm in the UK).

The data is expected to show a slowdown – or worse – across the US economy over the quarter. Estimates range from annualised growth of 1.7%, to an annualised contraction of 1.5%.

If GDP falls, then the US would be on the brink of a technical recession (defined as two quarters of negative growth in a row).

The US expanded by 2.4% per year in the final quarter of 2024.

There’s concern that a surge in imports in the last quarter could weigh on growth, after data yesterday showed the US trade in goods deficit widened sharply in March.

Analysts at French bank BNP Paribas have revised down their estimate for US Q1 real GDP growth to -0.6% quarter-on-quarter, from a previous forecast of +0.4%, “mainly due to March data showing a wider goods trade deficit”.

Share

Updated at 

Key events

GSK ‘well-prepared’ for Trump tariffs

Joanna Partridge

British pharma company GSK said it was “well-prepared” for any possible tariffs imposed by Donald Trump on the pharma sector.

“As far as tariffs are concerned, we start from a position of strength,” GSK’s chief executive Emma Walmsley told reporters as the company announced its first quarter results.

Walmsley said:

“Obviously there’s still some fluidity here. We’re watching it very carefully, but we are well-prepared, have been working on that for some time, to navigate and mitigate.”

The pharma sector has been holding its breath in the face of threatened tariffs from the US. The sector has been largely exempt from duties under a 1995 World Trade Organization (WTO) agreement, designed to keep medicines affordable.

Walmsley made clear that the US was GSK’s “number one market” for investment as well as for “innovation commercially … where we invest in R&D … in manufacturing” and in business development.

She said GSK had “reset” its supply chain in 2022 when it separated its consumer healthcare business from the rest of the group to form Haleon, a separate listed company, rather than responding to the threat of tariffs.

She added:

“When we went through the demerger, there was an enormous amount of work to make very intentional, deliberate choices to reset our supply chain for regional resilience and dual sourcing and quite a bit of flexibility.”

GSK broke ground on its sixth factory in the US earlier this month, she said.

It came as the company reported a 4% rise in sales in the first three months of the year to £7.5bn, ignoring currency movements, and reconfirmed its guidance for the rest of the year.





Source link

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe

Latest Articles